San Francisco · CA, USA · founded 2022 · http://www.lyggcorp.com
Diligence memoA one-page analyst read on Lygg — recommendation, valuation, rhythm, risks.→Lygg: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Building New Anti-Aging Ingredients for Skincare
Up to 90% of skin aging is caused by UV light from the sun. Most of this is caused by UVA light and only one FDA-approved chemical ingredient protects against it. To address this, Lygg has developed a patented, photostable, and safe ingredient that triples current UVA protection.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 8525 companies in this sector. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 96% of sector peers (real $). Modeled value above 96% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Lygg is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| SOTERI SKIN D2C Skincare for Eczema | Ecommerce / Retail | — | — | 67% |
| Photoswitch Biosciences, Inc. | Biotechnology | Pre-Seed | $27.6M | 67% |
| ZO Skin Health, Inc. | Pharmaceuticals | Series A | $185.8M | 66% |
| Skincure Oncology Llc | Pharma | Series B | $1.0B | 66% |
| PROVEN Group, Inc. PROVEN is using AI, data and personalization to disrupt CPG | AI / ML | Series A | $238.8M | 65% |
| Applied UV, Inc. | Other Health Care | Series A | $115.5M | 65% |
| Eat Blueprint Longevity Nutrition Service | — | — | — | 65% |
| AesculaTech Responsive materials, better lives. | — | — | — | 65% |
See where Lygg sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Lygg, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.